Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy

[1]  I. Casaburi,et al.  Antitumoral Activities of Curcumin and Recent Advances to ImProve Its Oral Bioavailability , 2021, Biomedicines.

[2]  Helen K. Matthews,et al.  Cell cycle control in cancer , 2021, Nature Reviews Molecular Cell Biology.

[3]  L. Saraíva,et al.  Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target , 2021, Cancers.

[4]  Junchao Dong,et al.  ATR kinase activity promotes antibody class switch recombination in B cells through cell cycle regulation without suppressing DSB resection and microhomology usage. , 2021, Journal of leukocyte biology.

[5]  S. Boddu,et al.  Resveratrol‐loaded nanomedicines for cancer applications , 2021, Cancer reports.

[6]  L. Górecki,et al.  Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer , 2021, Cancers.

[7]  M. Uspenskaya,et al.  Mangiferin as New Potential Anti-Cancer Agent and Mangiferin-Integrated Polymer Systems—A Novel Research Direction , 2021, Biomolecules.

[8]  M. Altmeyer,et al.  The Hammer and the Dance of Cell Cycle Control. , 2020, Trends in biochemical sciences.

[9]  Elise Adrian Ostrander,et al.  Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications , 2020, Frontiers in Pharmacology.

[10]  R. Capasso,et al.  Anticancer Potential of Furanocoumarins: Mechanistic and Therapeutic Aspects , 2020, International journal of molecular sciences.

[11]  C. Mussolino,et al.  DNA Damage: From Threat to Treatment , 2020, Cells.

[12]  Y. Liu,et al.  Curcumin-Induced DNA Demethylation in Human Gastric Cancer Cells Is Mediated by the DNA-Damage Response Pathway , 2020, Oxidative medicine and cellular longevity.

[13]  N. Curtin,et al.  DNA damage checkpoint kinases in cancer , 2020, Expert Reviews in Molecular Medicine.

[14]  P. Zhou,et al.  DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer , 2020, Signal Transduction and Targeted Therapy.

[15]  P. Zhu,et al.  A Comprehensive Review on Schisandrin B and Its Biological Properties , 2020, Oxidative medicine and cellular longevity.

[16]  P. Ranjekar,et al.  Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice , 2020, Frontiers in Pharmacology.

[17]  Y. Drew,et al.  Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations? , 2019, Pharmacology & therapeutics.

[18]  Muhammad Mohtasheemul Hasan,et al.  Apoptosis induced by luteolin in breast cancer: Mechanistic and therapeutic perspectives. , 2019, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[19]  K. Harrington,et al.  PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours , 2018, Clinical and translational radiation oncology.

[20]  N. Oleinick,et al.  ATR/CHK1 inhibitors and cancer therapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  K. Cimprich,et al.  The essential kinase ATR: ensuring faithful duplication of a challenging genome , 2017, Nature Reviews Molecular Cell Biology.

[22]  H. Rupasinghe,et al.  Apple Flavonoids Suppress Carcinogen-Induced DNA Damage in Normal Human Bronchial Epithelial Cells , 2017, Oxidative medicine and cellular longevity.

[23]  M. Joerger,et al.  RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies , 2017, International journal of cancer.

[24]  Y. Drew,et al.  Targeting the ATR-CHK1 Axis in Cancer Therapy , 2017, Cancers.

[25]  R. Benhida,et al.  ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells. , 2017, MedChemComm.

[26]  W. Haas,et al.  Coupling of Homologous Recombination and the Checkpoint by ATR. , 2017, Molecular cell.

[27]  L. Zou,et al.  Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway. , 2016, Annual review of genetics.

[28]  M. Galsky,et al.  Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors , 2016, Oncology.

[29]  Iwu Irenus Chinonye,et al.  Phytochemicals and Antimicrobial Properties of the Root and Leaf Extract of Carica Papaya , 2016 .

[30]  G. Shapiro,et al.  Abstract CT012: Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792) , 2016 .

[31]  David A. Smith,et al.  Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer , 2016, Investigational New Drugs.

[32]  M. Ranson,et al.  Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792). , 2016 .

[33]  N. Tunariu,et al.  Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies. , 2016 .

[34]  O. Fernandez-Capetillo,et al.  A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors. , 2016, Molecular cell.

[35]  S. Hansen,et al.  Expression and prognostic value of the WEE1 kinase in gliomas , 2016, Journal of Neuro-Oncology.

[36]  Y. Wu,et al.  ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer , 2015, Oncotarget.

[37]  T. Yoshino,et al.  Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors , 2015, Anti-cancer drugs.

[38]  D. Gillespie,et al.  DNA damage control: regulation and functions of checkpoint kinase 1 , 2015, The FEBS journal.

[39]  Fan Zhang,et al.  Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells , 2015, Cancer biology & therapy.

[40]  L. Karnitz,et al.  Molecular Pathways: Targeting ATR in Cancer Therapy , 2015, Clinical Cancer Research.

[41]  J. Benada,et al.  Targeting the Checkpoint to Kill Cancer Cells , 2015, Biomolecules.

[42]  J. Yang,et al.  Mangiferin induces cell cycle arrest at G2/M phase through ATR-Chk1 pathway in HL-60 leukemia cells. , 2015, Genetics and molecular research : GMR.

[43]  Jung-Hye Choi,et al.  Resveratrol analogue (E)-8-acetoxy-2-[2-(3,4-diacetoxyphenyl)ethenyl]-quinazoline induces G₂/M cell cycle arrest through the activation of ATM/ATR in human cervical carcinoma HeLa cells. , 2015, Oncology reports.

[44]  A. Ryan,et al.  ATM and ATR as therapeutic targets in cancer. , 2015, Pharmacology & therapeutics.

[45]  Jing-Gung Chung,et al.  Kaempferol induces DNA damage and inhibits DNA repair associated protein expressions in human promyelocytic leukemia HL-60 cells. , 2015, The American journal of Chinese medicine.

[46]  A. Venook,et al.  Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Graham Ball,et al.  Untangling the ATR‐CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer , 2015, Molecular oncology.

[48]  I. Vitale,et al.  Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy , 2015, Molecular & Cellular Oncology.

[49]  Le Wang,et al.  The effect of caffeine on cisplatin-induced apoptosis of lung cancer cells , 2015, Experimental Hematology & Oncology.

[50]  M. Boerries,et al.  The natural anticancer compound rocaglamide selectively inhibits the G1‐S‐phase transition in cancer cells through the ATM/ATR‐mediated Chk1/2 cell cycle checkpoints , 2014, International journal of cancer.

[51]  Youwei Zhang,et al.  Roles of Chk1 in cell biology and cancer therapy , 2014, International journal of cancer.

[52]  E. Sausville,et al.  Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[53]  K. Cimprich,et al.  Causes and consequences of replication stress , 2013, Nature Cell Biology.

[54]  H. Ogiwara,et al.  Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor. , 2013, Carcinogenesis.

[55]  L. Zou,et al.  DNA damage sensing by the ATM and ATR kinases. , 2013, Cold Spring Harbor perspectives in biology.

[56]  I. Collins,et al.  Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies , 2013, Expert opinion on drug discovery.

[57]  Yung-Liang Chen,et al.  Triptolide induced DNA damage in A375.S2 human malignant melanoma cells is mediated via reduction of DNA repair genes. , 2013, Oncology reports.

[58]  A. Hidalgo-Miranda,et al.  Resveratrol induces downregulation of DNA repair genes in MCF-7 human breast cancer cells , 2013, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[59]  A. Jemal,et al.  Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. , 2012, The Lancet. Oncology.

[60]  T. Shen,et al.  The role of Cdc25A in the regulation of cell proliferation and apoptosis. , 2012, Anti-cancer agents in medicinal chemistry.

[61]  Hui-Chun Wang,et al.  Inhibition of ATR-Dependent Signaling by Protoapigenone and Its Derivative Sensitizes Cancer Cells to Interstrand Cross-link–Generating Agents In Vitro and In Vivo , 2012, Molecular Cancer Therapeutics.

[62]  Y. Maehara,et al.  ATR-ATRIP kinase complex triggers activation of the Fanconi anemia DNA repair pathway. , 2012, Cancer research.

[63]  T. Lawrence,et al.  Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1 , 2011, Cell cycle.

[64]  R. Syljuåsen,et al.  Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication , 2011, Nucleic acids research.

[65]  J. Sarkaria,et al.  Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines , 2011, British Journal of Cancer.

[66]  P. Reaper,et al.  Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. , 2011, Nature chemical biology.

[67]  E. Nam,et al.  ATR signalling: more than meeting at the fork. , 2011, The Biochemical journal.

[68]  Yun Dai,et al.  CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. , 2011, Molecular interventions.

[69]  Dietrich Büsselberg,et al.  Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects , 2011, Cancers.

[70]  W. Seghezzi,et al.  Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening , 2011, Molecular Cancer Therapeutics.

[71]  H. Piwnica-Worms,et al.  Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. , 2011, Trends in molecular medicine.

[72]  William M. Lee,et al.  Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. , 2010, Gastroenterology.

[73]  Yun Dai,et al.  New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network , 2010, Clinical Cancer Research.

[74]  K. Ko,et al.  Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response , 2009, Nucleic acids research.

[75]  L. Zou,et al.  ATR signaling at a glance , 2009, Journal of Cell Science.

[76]  Jonathan Maybaum,et al.  Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells , 2009, Molecular Cancer Therapeutics.

[77]  K. Cimprich,et al.  ATR: an essential regulator of genome integrity , 2008, Nature Reviews Molecular Cell Biology.

[78]  R. Zhao,et al.  TopBP1 activates ATR through ATRIP and a PIKK regulatory domain. , 2008, Genes & development.

[79]  T. Dörk,et al.  Resveratrol modulates DNA double-strand break repair pathways in an ATM/ATR-p53- and -Nbs1-dependent manner. , 2008, Carcinogenesis.

[80]  K. Cimprich,et al.  The ATR pathway: fine-tuning the fork. , 2007, DNA repair.

[81]  K. Cimprich,et al.  The structural determinants of checkpoint activation. , 2007, Genes & development.

[82]  W. Chazin,et al.  Function of a Conserved Checkpoint Recruitment Domain in ATRIP Proteins , 2007, Molecular and Cellular Biology.

[83]  Y. Zou,et al.  ATR-dependent checkpoint modulates XPA nuclear import in response to UV irradiation , 2007, Oncogene.

[84]  Hidetaka Kobayashi,et al.  Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint , 2007, Molecular Cancer Therapeutics.

[85]  L. Karnitz,et al.  Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo , 2007, Cell cycle.

[86]  R. Buttyan,et al.  Anti-prostate cancer activity of a beta-carboline alkaloid enriched extract from Rauwolfia vomitoria. , 2006, International journal of oncology.

[87]  N. Mailand,et al.  Claspin Operates Downstream of TopBP1 To Direct ATR Signaling towards Chk1 Activation , 2006, Molecular and Cellular Biology.

[88]  A. Carr,et al.  Identification and functional analysis of TopBP1 and its homologs. , 2005, DNA repair.

[89]  R. Agarwal,et al.  Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. , 2005, Carcinogenesis.

[90]  Tao Wang,et al.  Schisandrin B--a novel inhibitor of P-glycoprotein. , 2005, Biochemical and biophysical research communications.

[91]  Jiri Bartek,et al.  The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair , 2005, Nature Cell Biology.

[92]  H. Piwnica-Worms,et al.  Chk1 Kinase Negatively Regulates Mitotic Function of Cdc25A Phosphatase through 14-3-3 Binding , 2003, Molecular and Cellular Biology.

[93]  E. Yazlovitskaya,et al.  Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin. , 2003, Anticancer research.

[94]  J. Bartek,et al.  Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. , 2003, Cancer cell.

[95]  Jun Qin,et al.  ATR and ATRIP: Partners in Checkpoint Signaling , 2001, Science.

[96]  A. Kumagai,et al.  Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. , 2001, Molecular biology of the cell.

[97]  S. Elledge,et al.  Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. , 2000, Genes & development.

[98]  A. Kumagai,et al.  Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts. , 2000, Molecular cell.

[99]  Y. A. Minamishima,et al.  Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. , 2000, Genes & development.

[100]  S. Elledge,et al.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.

[101]  G. Schwartsmann,et al.  Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds. , 2000, The oncologist.

[102]  D. Baltimore,et al.  ATR disruption leads to chromosomal fragmentation and early embryonic lethality. , 2000, Genes & development.

[103]  J. Sarkaria,et al.  Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. , 1999, Cancer research.

[104]  A. Eastman,et al.  Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[105]  R. Bernards,et al.  rad-Dependent Response of the chk1-Encoded Protein Kinase at the DNA Damage Checkpoint , 1996, Science.

[106]  A. Eastman,et al.  The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[107]  N. S. Kumar,et al.  The surprising health benefits of papaya seeds: A review , 2017 .

[108]  Y. Wu,et al.  ATR-Chk 1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer , 2016 .

[109]  Lye Mun Tho,et al.  The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. , 2010, Advances in cancer research.

[110]  S. Schreiber,et al.  Overexpression of a kinase‐inactive ATR protein causes sensitivity to DNA‐damaging agents and defects in cell cycle checkpoints , 1998, The EMBO journal.